Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Rhea-AI Summary

Lexaria (Nasdaq:LEXX) announced an extension to its Material Transfer Agreement with a pharmaceutical company through April 30, 2026 to allow PharmaCO time to receive and review the full dataset from Lexaria's Australian human study GLP-1-H24-4.

The extension keeps the temporary exclusive license active and preserves the parties' ability to continue strategic planning with PharmaCO's human clinical development team. Lexaria said initial pre-clinical pharmacokinetic animal studies under the MTA were completed earlier in 2025 and that final results from the Australian study are projected to be released before the end of Q4 2025.

Positive

• MTA extended through April 30, 2026
• Temporary exclusive license remains active
• Final Australian study results projected before end of Q4 2025
• Pre-clinical pharmacokinetic animal studies completed in 2025

Negative

• PharmaCO review caused timeline extension to April 30, 2026
• Next steps contingent on PharmaCO's receipt and review of full dataset

KELOWNA, BC / ACCESS Newswire / November 12, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this update on the Material Transfer Agreement ("MTA") originally entered into on September 4, 2024 with a pharmaceutical company ("PharmaCO") to evaluate Lexaria's DehydraTECH^TM technology in a pre-clinical setting.

The original agreement has been extended through April 30, 2026, to accommodate time needed for PharmaCO's receipt and review of the full dataset from Lexaria's Australian study, at which time further information will be provided. This allows the two parties to continue their relationship under the MTA, keep the temporary exclusive license active and in force, and contemplate additional strategic planning discussions with PharmaCO's human clinical development team.

Earlier in 2025, initial pre-clinical studies covered by the MTA, which examined pharmacokinetics in animals, had been completed. At that time, Lexaria had been informed by PharmaCO that they wished to review the pending safety (adverse events), pharmacokinetic and efficacy data from Lexaria's independent, Australian human clinical study GLP-1-H24-4, which is currently at the stage of full sample and data analyses as previously announced. Lexaria expects to release the final results of the Australian study when available, which is currently projected to be before the end of the fourth quarter of calendar 2025.

About Lexaria Bioscience Corp. & DehydraTECH

DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 54 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:

George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202

SOURCE: Lexaria Bioscience Corp.

View the original press release on ACCESS Newswire

FAQ

What did Lexaria (LEXX) announce on November 12, 2025 about the Material Transfer Agreement?

Lexaria said the MTA with a pharmaceutical company was extended through April 30, 2026 to allow review of the Australian study dataset.

How does the MTA extension affect Lexaria's temporary exclusive license (LEXX)?

The extension keeps the temporary exclusive license active and in force while parties continue strategic planning.

When does Lexaria expect to release final results for the Australian study GLP-1-H24-4 (LEXX)?

Lexaria projects final results will be released before the end of Q4 2025.

What pre-clinical work completed under the MTA did Lexaria report (LEXX)?

Lexaria reported initial pre-clinical studies examining pharmacokinetics in animals were completed in 2025.

Why was the MTA between Lexaria and PharmaCO extended to April 30, 2026?

The extension was to accommodate PharmaCO's receipt and review of Lexaria's full dataset from the Australian study.